SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for
Ahmed Ashour Ahmed1, Zhen Lu, Nicholas B Jennings
1Department of Experimental Therapeutics, M.D. Anderson Cancer Center, University of Texas, Houston, 77030, USA. ahmed.ahmed@obs-gyn.ox.ac.uk
Abstract:
Regulators of mitosis have been successfully targeted to enhance response to taxane chemotherapy. Here, we show that the salt inducible kinase 2 (SIK2) localizes at the centrosome, plays a key role in the initiation of mitosis, and regulates the localization of the centrosome linker protein, C-Nap1, through S2392 phosphorylation. Interference with the known SIK2 inhibitor PKA induced SIK2-dependent centrosome splitting in interphase while SIK2 depletion blocked centrosome separation in mitosis, sensitizing ovarian cancers to paclitaxel in culture and in xenografts. Depletion of SIK2 also delayed G1/S transition and reduced AKT phosphorylation. Higher expression of SIK2 significantly correlated with poor survival in patients with high-grade serous ovarian cancers. We believe these data identify SIK2 as a plausible target for therapy in ovarian cancers.
Insights
Salt inducible kinase 2 (SIK2) is crucial for mitosis and centrosome separation. Inhibiting SIK2 sensitizes ovarian cancers to paclitaxel, suggesting SIK2 as a potential therapeutic target for ovarian cancer.
Area of Science:
- Cell Biology
- Molecular Oncology
Background:
- Mitotic regulators are key targets for enhancing chemotherapy response.
- Salt inducible kinase 2 (SIK2) is implicated in cell cycle regulation.
Purpose of the Study:
- To investigate the role of SIK2 in mitosis and its potential as a therapeutic target in ovarian cancer.
- To determine if SIK2 regulates centrosome function and impacts response to paclitaxel.
Main Methods:
- Immunofluorescence to determine SIK2 localization at the centrosome.
- Functional assays involving SIK2 inhibition and depletion.
- Cell culture and xenograft models of ovarian cancer.
- Analysis of patient survival data.
Main Results:
- SIK2 localizes to the centrosome and regulates C-Nap1 localization via phosphorylation.
- SIK2 depletion blocks centrosome separation, sensitizing ovarian cancer cells to paclitaxel.
- SIK2 inhibition leads to centrosome splitting in interphase.
- SIK2 depletion delays G1/S transition and reduces AKT phosphorylation.
- High SIK2 expression correlates with poor survival in ovarian cancer patients.
Conclusions:
- SIK2 plays a critical role in mitotic progression and centrosome dynamics.
- Targeting SIK2 enhances sensitivity to paclitaxel in ovarian cancer models.
- SIK2 represents a promising therapeutic target for ovarian cancer treatment.
Related Concept Videos
Meiosis II
The timing and cell division patterns of meiosis differ between males and females. In male meiosis, the centrosomes are part of the formation of the meiotic spindle. However, in oocytes, including that of humans, Drosophila,...
Meiosis II
Centrosome Duplication
To ensure that each daughter cell receives a centrosome after cell division, centrosome duplication...
Centrosome Duplication
To ensure that each daughter cell receives a centrosome after cell division, centrosome duplication...
The Mitotic Spindle
The bipolar configuration of the mitotic spindle facilitates chromosomal segregation, preparing the cell for division. One mechanism that ensures bipolar mitotic...
The Mitotic Spindle
The bipolar configuration of the mitotic spindle facilitates chromosomal segregation, preparing the cell for division. One mechanism that ensures bipolar mitotic...


